These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2221860)

  • 1. Meropenem pharmacokinetics and penetration into an inflammatory exudate.
    Wise R; Logan M; Cooper M; Ashby JP; Andrews JM
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1515-7. PubMed ID: 2221860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of meropenem in experimentally burned rats.
    Yoshida T; Homma K; Azami K; Sugihara T; Ohura T
    J Dermatol; 1993 Apr; 20(4):208-13. PubMed ID: 8315110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and tissue penetration of imipenem.
    Wise R; Donovan IA; Lockley MR; Drumm J; Andrews JM
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():93-101. PubMed ID: 3102453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.
    Johnson JH; Cooper MA; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2444-6. PubMed ID: 1336947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.
    Wise R; Andrews JM; Ashby JP; Marshall J
    J Antimicrob Chemother; 1999 Nov; 44(5):701-4. PubMed ID: 10552990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.
    Child J; Mortiboy D; Andrews JM; Chow AT; Wise R
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2749-51. PubMed ID: 8593013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenylbutazone and oxyphenbutazone distribution into tissue fluids in the horse.
    Lees P; Taylor JB; Higgins AJ; Sharma SC
    J Vet Pharmacol Ther; 1986 Jun; 9(2):204-12. PubMed ID: 3723663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.
    Wise R; Logan M; Cooper M; Andrews JM
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1081-4. PubMed ID: 1656853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.
    Wise R; Gee T; Marshall G; Andrews JM
    Antimicrob Agents Chemother; 2002 Jan; 46(1):242-4. PubMed ID: 11751144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pharmacokinetics and urine concentrations of meropenem in ewes.
    Abo El Sooud K
    J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of meropenem in patients with intra-abdominal infections.
    Bedikian A; Okamoto MP; Nakahiro RK; Farino J; Heseltine PN; Appleman MD; Yellin AE; Berne TV; Gill MA
    Antimicrob Agents Chemother; 1994 Jan; 38(1):151-4. PubMed ID: 8141572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.
    O'Neill P; Nye K; Douce G; Andrews J; Wise R
    Antimicrob Agents Chemother; 1990 Feb; 34(2):232-4. PubMed ID: 2327771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of meropenem in subjects with renal insufficiency.
    Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
    Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
    Wise R; Mortiboy D; Child J; Andrews JM
    Antimicrob Agents Chemother; 1996 Jan; 40(1):47-9. PubMed ID: 8787877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disposition and metabolic fate of 14C-meropenem in man.
    Harrison MP; Haworth SJ; Moss SR; Wilkinson DM; Featherstone A
    Xenobiotica; 1993 Nov; 23(11):1311-23. PubMed ID: 8310714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
    Maglio D; Teng R; Thyrum PT; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2003 May; 47(5):1771-3. PubMed ID: 12709358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.
    Mouton JW; Michel MF
    J Antimicrob Chemother; 1991 Dec; 28(6):911-8. PubMed ID: 1816187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of meropenem in volunteers.
    Bax RP; Bastain W; Featherstone A; Wilkinson DM; Hutchison M; Haworth SJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():311-20. PubMed ID: 2808215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin.
    Cooper MA; Nye K; Andrews JM; Wise R
    J Antimicrob Chemother; 1990 Oct; 26(4):533-8. PubMed ID: 2174853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model.
    Hashizume T; Okumoto Y; Ogashiwa M; Shimano K
    J Antimicrob Chemother; 1987 Sep; 20(3):413-6. PubMed ID: 3119555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.